Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -35% Improvement Relative Risk c19hcq.org Albanghali et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 811 patients in Saudi Arabia Higher mortality with HCQ (not stat. sig., p=0.46) Albanghali et al., J. Infection and Public Health, doi:10.1016/j.jiph.2022.02.001 Favors HCQ Favors control
Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A Single Centre Study
Albanghali et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.02.001
Albanghali et al., Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A.., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.02.001
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 811 hospitalized COVID+ patients in Saudi Arabia, showing higher mortality with HCQ treatment in unadjusted results subject to confounding by indication. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; substantial unadjusted confounding by indication likely.
risk of death, 34.6% higher, RR 1.35, p = 0.46, treatment 20 of 466 (4.3%), control 11 of 345 (3.2%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Albanghali et al., 3 Feb 2022, retrospective, Saudi Arabia, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A Single Centre Study Mohammad Albanghali, Saleh Alghamdi, Mohammed Alzahrani, Bassant Barakat, Abdul Haseeb, Jonaid Ahmad Malik, Sakeel Ahmed, Sirajudheen Anwar PII: S1876-0341(22)00034-X DOI: https://doi.org/10.1016/j.jiph.2022.02.001 Reference: JIPH1808 To appear in: Journal of Infection and Public Health Received date: 12 June 2021 Revised date: 29 January 2022 Accepted date: 1 February 2022 Please cite this article as: Mohammad Albanghali, Saleh Alghamdi, Mohammed Alzahrani, Bassant Barakat, Abdul Haseeb, Jonaid Ahmad Malik, Sakeel Ahmed and Sirajudheen Anwar, Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A Single Centre Study, Journal of Infection and Public Health, (2021) doi:https://doi.org/10.1016/j.jiph.2022.02.001 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier. Clinical Characteristics and Treatment Outcomes of Mild to Moderate Covid-19 Patients in Saudi Arabia: A Single Centre Study Mohammad Albanghali1, Saleh Alghamdi2, Mohammed Alzahrani3, Bassant Barakat2, Abdul 1 Department of Public Health, Faculty of Applied Medical Sciences, Albaha University, pr Albaha, Saudi Arabia; email: mohammad.aref@bu.edu.sa 2 oo f Haseeb4, Jonaid Ahmad Malik5 , Sakeel Ahmed6 , Sirajudheen Anwar7* Department of Clinical Pharmacy, Faculty of Clinical Pharmacy, Albaha University, 3 e- Albaha, Saudi Arabia; email: bbarakat@bu.edu.sa , saleh.alghamdi@bu.edu.sa Pharmaceutical care services department, King Fahad Hospital, Albaha, Saudi Arabia; 4 Pr email: malzahrani172@moh.gov.sa Department of Clinical pharmacy, College of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia; email: amhaseeb@uqu.edu.sa Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education al 5 6 ur n and Research, Guwahati, India Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Mohali, India Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Jo 7 Hail, Saudi Arabia; email: si.anwar@uoh.edu.sa Running title: Clinical Outcomes in mild COVID-19 patients. * Corresponding author: Dr. Sirajudheen Anwar, Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia E-mail address: (si.anwar@uoh.edu.sa) 1 Abstract Objective: Since the severity of symptoms affects the treatment option for Coronavirus Disease 2019 (COVID-19) patients, the treatment pattern for mild to moderate non-ICU cases must be evaluated, particularly in the current scenario of mutation and variant strain for effective decision making. Methods: The objective of retrospective analysis was to assess clinical and treatment oo f outcomes in mild to moderate symptoms in non-ICU patients with COVID-19..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit